Bioanalysis Errors: How to Spot and Fix Them Early

In the bioanalytical lab, we like to say that the data is only as good as the method that generated it. But after years of seeing projects stall at the validation stage, I've realized that most failures don't happen because the technology is lacking-they happen because we overlook the subtle, "boring" details during early development.

When you're moving a drug toward a regulatory filing, a bioanalysis error isn't just a technical glitch; it's a million-dollar delay. As a preclinical CRO, we've inherited countless "broken" methods that worked perfectly in a small-scale pilot but crumbled under the rigors of GLP validation.

Here is my take on the real-world pitfalls that will derail your assay and how to fix them before they become an auditor's headache.

1. Sample Preparation: The Recovery and Stability Challenge

Errors often occur before the sample is even injected into the instrument. If your drug isn't reaching the detector, the method is fundamentally flawed.

Addressing Non-Specific Binding

Many analytes-particularly hydrophobic small molecules and large proteins-tend to adhere to the plastic surfaces of tubes and pipette tips.

• The Issue: This "adsorption" leads to poor recovery and inconsistent data.
• The Practice: Don't wait until the validation phase to test for this. Use low-protein binding tubes from day one. If adsorption persists, consider adjusting the pH or adding a small amount of surfactant to keep the analyte in the liquid phase. Recent literature indicates that even a 5% loss at each transfer step can significantly impact reproducibility.

Managing Bench-Top Stability

Stability is more than just long-term storage. The most critical window is often the time a sample spends on the bench during processing.

• The Issue: If an analyte is sensitive to light or temperature, degradation can occur during the extraction process.
• The Practice: Method development must include "stress tests" for bench-top stability. If a technician handles a large batch of samples, will the last sample in the queue still be intact? Proving stability under these operational conditions is essential for successful Incurred Sample Reanalysis (ISR).

2. Technical LC-MS Issues: Identifying Interference

The sensitivity of LC-MS/MS makes it vulnerable to external factors that are often difficult to detect without specific testing.

The Matrix Effect

This is perhaps the most common cause of LC-MS issues. It occurs when components from the biological sample (like phospholipids or salts) compete with your drug for ionization.

• The Result: You might see a strong signal for your standards, but a weak or erratic signal in real biological samples.
• The Solution: We utilize the Post-Column Infusion Test. By infusing the drug at a constant rate while injecting a blank matrix sample, we can map out the zones where signal suppression occurs. If the drug elutes in a suppression zone, the chromatography must be adjusted to move the peak into a cleaner window.

Managing Carryover

Carryover-where drug from a previous injection remains in the system-can lead to false positives in blank samples.

• The Practice: Standard needle washes are often insufficient for high-sensitivity assays. A multi-solvent wash (e.g., alternating between aqueous and organic solvents) is usually necessary to ensure the system is clean between every injection.

3. The Internal Standard (IS): Precision vs. Cost

The choice of an Internal Standard is one of the most critical decisions in method development.

SIL-IS vs. Structural Analogs

• The Pitfall: Using a structural analog (a molecule that looks similar to the drug) is a common way to reduce costs. However, analogs rarely elute at the exact same time as the drug, meaning they don't experience the same matrix effects or ionization conditions.
• The Standard: Recent studies and regulatory feedback consistently emphasize the use of Stable Isotope Labeled (SIL) standards. Because they are chemically identical to the drug but different in mass, they track the analyte perfectly through every step, significantly reducing assay validation problems.

4. Why Incurred Sample Reanalysis (ISR) Often Fails

ISR is the ultimate test of a method's robustness. It involves re-analyzing real study samples to ensure the results can be replicated.

Root Causes of Failure

Analysis of failed ISR cases typically points to two areas:

• Sample Homogeneity: If a sample is not thoroughly mixed after thawing, the drug concentration will not be uniform.
• Method Robustness: If a method only works when conditions are perfect (e.g., a brand-new column or a specific instrument), it will likely fail during a long-term study. We recommend "stress-testing" the method by intentionally varying flow rates or temperatures slightly during development to ensure the data remains stable.

The CRO Checklist: A Senior Scientist's Strategy

Before we move any method into validation, we run this "sanity check":

1. Check the IS tracking: Does the IS signal stay consistent across 100 injections?
2. Push the LLOQ: Is the signal-to-noise ratio at the limit of quantitation at least 5:1, or are we just looking at "fuzz"?
3. Scan the Matrix: Have we tested at least 6 different lots of matrix (including hemolyzed and lipemic samples)?
4. Test the "World-to-Chip" (for MPS/OoC): If we are doing organ-on-a-chip bioanalysis, is the drug sticking to the microfluidic tubing?

Final Thoughts: Quality is a Culture, not a Checklist

At the end of the day, avoiding bioanalysis errors comes down to one thing: curiosity. When you see an odd peak or a slight shift in retention time, don't ignore it. That "little quirk" is usually the warning sign of a major assay validation problem waiting to happen.

Build your methods to be "bulletproof," not just "good enough." In this industry, the most expensive data is the data you can't use.

Creative Bioarray Relevant Recommendations

Reference

1. Ferreira V G, Feitor J F, et al. What Is Bioanalytical Chemistry? Scientific Opportunities with Immediate Impact. In: Kubota, L.T., da Silva, J.A.F., Sena, M.M., Alves, W.A. (eds) Tools and Trends in Bioanalytical Chemistry. Springer, 2022